There are a range of therapeutic options available for the management of type 2 diabetes in the elderly. Diet remains the mainstay of treatment although this must be realistic. If diet alone is unsuccessful then, for most patients, short-acting sulphonylurea agents are the treatment of choice. Second line agents include the biguanide, metformin, or an α-glucosidase inhibitor. A significant proportion of type 2 diabetic patients will, however, eventually require insulin to alleviate symptoms of poor control and improve glycaemia. In this article I discuss the therapeutic options available for diabetic management in the elderly, with particular emphasis on the pros and cons of insulin treatment.
MannJILewis-BarnedNJ. Dietary management of diabetes mellitus in Europe and North America. In: AlbertiKGMMDefronzoRAKeenHZimmetP, eds. International Textbook of Diabetes Mellitus. Chichester: John Wiley and Sons, 1992:685–700.
2.
HoskerJPBurnettMADaviesEGTurnerRC. Sulphonylurea therapy doubles beta-cell response to glucose in type 2 diabetic patients. Diabetologia1985;28:809–14.
3.
FeinglosMNLeboritzHE. Sulphonylureas increase the number of insulin receptors. Nature1978;275:184–5.
4.
AsplundKWilholmBLithnerF. Glibenclamide associated hypoglycaemia: a report on 57 cases. Diabetologia1983;24:412–17.
5.
CampbellIW. Metformin and the sulphonylureas: the comparative risks. Horm Metab Res Suppl1985;15:105–11.
6.
PragerRSchernthanerGGrafH. Effect of metformin on peripheral insulin sensitivity in non-insulin dependent diabetes mellitus. Diabete Metab1986;12:346–50.
7.
GawlerDJMilliganGHouslayMD. Treatment of streptozotocin diabetic rats with metformin restores the ability of insulin to inhibit adenylate cyclase activity. Biochem J1988;249:537–42.
8.
RyderRE. Lactic acidosis: high dose or low-dose bicarbonate therapy. Diabetes Care1984;7:99–102.
9.
CrentzfeldW (ed.). Proceedings Second International Symposium, Acarbose, Berlin (1987). Berlin: Springer Verlag, 1988.
10.
TchobroutskyG. Relation of diabetic control to development of microvascular complications. Diabetologia1978;15:143–52.
11.
LauritzenTLarsenHWDeckertT, Steno Study Group. Two years experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes1985; 34(suppl 3):74–9.
12.
The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. J Am Med Assoc1988;260:37–41.
13.
Brinchmann-HansenODahl-JorgensenKSandrikLHanssenKF. Blood glucose concentrations and progression of diabetic retinopathy: the seven years results of the Oslo study. BMJ1992;304:19–22.
14.
ReichardPBerglundBBritzACarsINilssonBYRosenqvistU. Intensified conventional insulin retards the microvascular complications of insulin-dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med1991;230:101–8.
15.
Diabetes Control and Complications Trial Research Group. The effect on intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977–86.
16.
TaylorR. Use of insulin in non-insulin dependent diabetes. Diabetes Rev1992;1:9–11.
17.
BergerW. Insulin therapy in the elderly Type 2 diabetic patient. Diabetes Res Clin Pract Suppl1988;1:24–8.
18.
PeacockITattersallRB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?BMJ1984;288:1956–9.
19.
GenuthS. Insulin use in NIDDM. Diabetes Care1990;13:1240–64.
RoweBRPizzeyMBarnettAH. A clinical evaluation of the B-D (Becton-Dickinson) pen as a delivery device for human insulin. Pract Diabetes1992;9:138–9.
22.
ElgrablyFCostagliolaDChwalowAJVarennePSlamaGTchobroutskyGInitiation of insulin treatment after 70 years of age: patient status two years later. Diabet Med1991;8:773–7.
